Open Access
CC BY-NC-ND 4.0 · Planta Medica International Open 2021; 8(01): e10-e18
DOI: 10.1055/a-1375-6570
Original Article

Carbamazepine Shows Plasma and Tissue Pharmacokinetic Interactions with Ajuga bracteosa Extract in Rats

Authors

  • Ejaz Ahmad

    1   Department of Chemistry, Government College University Lahore, Pakistan
  • Muhammad Jahangir

    1   Department of Chemistry, Government College University Lahore, Pakistan
  • Saiqa Ishtiaq

    2   Punjab University College of Pharmacy, University of Punjab, Lahore, Pakistan
  • Hafiz Muhammad Faizan Haider

    1   Department of Chemistry, Government College University Lahore, Pakistan
  • Pervaiz Akhtar Shah

    2   Punjab University College of Pharmacy, University of Punjab, Lahore, Pakistan
  • Nadeem Irfan Bukhari

    2   Punjab University College of Pharmacy, University of Punjab, Lahore, Pakistan

Abstract

Carbamazepine (CBZ) is the first-line anticonvulsant drug with a narrow therapeutic index (NTI) and is a substrate for CYP3A4 and MRP-2. Ajuga bracteosa (AB), family Lamiaceae is widely used to treat epilepsy, gastric diseases, and protects against liver damage in folk. It contains bioactive metabolites, which are powerful inhibitors of CYP3A4, CYP3A5, CYP19, CYP2C19 enzymes and P-gp transporter. Concomitant use of NTI drugs with herbs, like AB increase the chances of herb-drug interactions (HDIs). This study was aimed to analyze the Ajuga bracteosa crude extract (ABCE) and to investigate its effect on the pharmacokinetics of CBZ in rats. In the pre-treatment study, rats received ABCE (1000 mg/kg) orally for 14 days, followed by a single dose of CBZ (80 mg/kg) on the 15th day. In the co-administration study, single doses of ABCE and CBZ were administered concomitantly in one session. All the doses were administered in 0.5% carboxymethylcellulose (CMC) as a vehicle. HPLC analysis showed that extract contained 1.3 mg/g ursolic acid, 2.1 mg/g sitosterol and 2.9 mg/g stigmasterol. Non-compartmental pharmacokinetic analysis showed an increase in Cmax, AUC0-∞, MRT, and t1/2 with a decrease in tmax, Vd and Cl of CBZ in both, pre-treated and co-administered groups vs controls. An increase in CBZ concentration in liver tissue of both pre-treated as well as co-administered animals was observed as compared to control. The above results suggested possible HDIs between AB and CBZ thus, may warrant CBZ dose adjustment in epileptic patients with simultaneous administration of AB or its products.



Publication History

Received: 17 August 2020
Received: 03 November 2020

Accepted: 25 January 2021

Article published online:
12 March 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany